NVO Novo-Nordisk A/S
- 128.420
- -0.240-0.19%
- 130.720
- +2.300+1.79%
Novo-Nordisk A/S News
US senators urge Denmark to pressure Novo Nordisk (NVO.US) to lower the price of diet pills
The Zhitong Finance App learned that on Monday, US Senator Bernie Sanders (Bernie Sanders) sent a letter to “Politiken” (Politiken), one of the largest newspapers in the Nordic countries, urging Denmark to put pressure on the well-known company NVO.US (NVO.US) to lower drug prices. According to reports, Sanders is the chairman of the US Senate Committee on Health, Education, Labor, and Pensions. He called on the Danes to put pressure on Novo Nordisk to “drastically reduce the ridiculously high prices of Ozempic and Wegovy in the US and the rest of the world.” In addition, Sanders also directly called on Novo Nordisk to drop
US Senator Bernie Sanders wrote to Politiken (Politiken), one of the largest newspapers in the Nordic countries, urging Denmark to put pressure on well-known company Novo Nordisk to lower drug prices.
US Senator Bernie Sanders wrote to Politiken (Politiken), one of the largest newspapers in the Nordic countries, urging Denmark to put pressure on well-known company Novo Nordisk to lower drug prices.
Sanders Urges Denmark to Pressure Novo Nordisk on Lowering Drug Prices
Bernie Sanders urged Denmark to force its most valuable company, Novo Nordisk A/S, to lower its drug prices, in a letter submitted by the US senator to one of the Nordic country’s largest newspapers.
One in Eight U.S. Adults Admits to GLP-1 Usage as Public Awareness Surges
“Weight loss elixir” is popular all over America! Research shows that 1 in 8 people have used it
More than half of those who have tried weight loss injections say it is difficult for them to afford them one after another; health insurance has not made these drugs more affordable, according to a survey.
Novavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps.
The two companies will also work on a shot that combines Covid-19 and flu vaccines.
Novo Nordisk lays out a “new racetrack” for weight loss drugs: US$600 million collaboration to develop “long-lasting treatments”
① Danish pharmaceutical company Novo Nordisk has signed a research cooperation agreement with the American biotech company Metaphore to jointly develop the next generation of diet pills; ② The treatment of the newly developed diet pills will be long-term, that is, patients will not need frequent medication; ③ The total amount of this cooperation is as high as 600 million US dollars, and Novo Nordisk promised to participate in Metaphore's future financing.
Next-Gen Obesity Drugs Gives Novo Nordisk (NYSE:NVO) a Lift
10 Health Care Stocks With Whale Alerts In Today's Session
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.
Top Midday Stories: Brookfield Q1 Revenue Down; Activist Investor Gets 3 Nominees Elected to Norfolk Southern Board; Nippon Steel Raising $1.61 Billion Ahead of Planned US Steel Acquisition
All three major US indexes were up in midday trading Thursday as the latest jobless claims data bolsters investors' hopes of monetary policy easing in the near future by the Federal Reserve. In compan
Novo Nordisk Partners With Metaphore Biotechnologies on New Obesity Drugs
By Helena Smolak Ozempic maker Novo Nordisk signed a research collaboration with U.S. biotech company Metaphore Biotechnologies to develop up to two advanced obesity treatments, which could cost the
The US stock diet drug concept market had mixed ups and downs at the beginning
Glonghui, May 9 | Novo Nordisk's ADR rose more than 0.9%, Lilly rose about 0.7%, Anjin rose more than 0.2%, Forte Pharmaceuticals fell more than 0.2%, and Bojian BIIB fell about 0.3%.
Novo Nordisk (NVO.US) invests $600 million to join Metaphor Biotech to build a new chapter in obesity treatment
Novo Nordisk announced a new research agreement with biotech company Metaphor Biotechnology.
Novo Nordisk Enters Research Partnership for New Weight Loss Drugs
Novo Nordisk (NOVO-B.CO) is planning an expansion to its obesity management portfolio with a new research collaboration deal. The Danish pharmaceutical company signed the agreement with Flagship's Met
Flagship Pioneering And Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk To Develop Next-Generation Therapeutics for Obesity Management, Novo Nordisk May Pay Up To $600M In Upfront, Development, And Commercial Milestone Payments
Flagship Pioneering And Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk To Develop Next-Generation Therapeutics for Obesity Management, Novo Nordisk May Pay Up To $600M In
Novo Nordisk May Pay Up to $600 Million in New R&D Deal
08:21 AM EDT, 05/09/2024 (MT Newswires) -- Novo Nordisk May Pay Up to $600 Million in New R&D Deal Price: 127.19, Change: +0.50, Percent Change: +0.39
Novo Nordisk Sets Sights on a Long-Lasting Successor to Its Weight Loss Blockbuster -- Barrons.com
By Josh Nathan-Kazis Novo Nordisk has ridden the monster wave of enthusiasm over Wegovy, its once-weekly obesity shot, to become Europe's most valuable company. Now, it says it is beginning work on a
Sudden changes in the capital trend of European stocks: “Ocean Eleven” consolidated, utility+real estate stocks “boomed”
Shares of Asmer, Novo Nordisk, and Ferrari fell even though profits were relatively in line with expectations; the ECB's interest rate cut cycle will boost utilities and small-cap stocks, and cheap stocks may provide downside protection.
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock.
Express News | Three major foundations, including the Novo Nordisk Foundation, have invested 300 million US dollars to support key research work in the field of global health
Analysis
Price Target
No Data
